公开(公告)号：US10793551B2

公开(公告)日：2020-10-06

申请号：US16162459

申请日：2018-10-17

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Alan X. Xiang

IPC: C07D403/04 ,  C07D401/14 ,  A61P35/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20190209560A1

公开(公告)日：2019-07-11

申请号：US16178678

申请日：2018-11-02

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: A61K31/506 ,  A61K31/551 ,  A61K31/52 ,  A61K31/519 ,  C07D519/00 ,  C07D495/20 ,  C07D471/04 ,  C07D471/20 ,  C07D471/10 ,  C07D487/04 ,  C07D473/34 ,  C07D491/20

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US11952375B2

公开(公告)日：2024-04-09

申请号：US17484564

申请日：2021-09-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: C07D471/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07B2200/13

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione:




The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20200339590A1

公开(公告)日：2020-10-29

申请号：US16804937

申请日：2020-02-28

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan X. Xiang ,  Christian Nilewski ,  Theo Michels

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US10577378B2

公开(公告)日：2020-03-03

申请号：US15917973

申请日：2018-03-12

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan X. Xiang ,  Christian Nilewski ,  Theo Michels

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20170266185A1

公开(公告)日：2017-09-21

申请号：US15611966

申请日：2017-06-02

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. ERNST

IPC: A61K31/506 ,  A61K31/52 ,  A61K31/519 ,  C07D487/04 ,  C07D473/34 ,  C07D519/00 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  C07D471/10 ,  C07D471/04 ,  A61K31/551

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US20170121346A1

公开(公告)日：2017-05-04

申请号：US15337184

申请日：2016-10-28

Applicant: eFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber ,  Mike Shaghafi ,  Douglas Murphy ,  Chinh Tran

IPC: C07D498/04 ,  C07D403/12 ,  C07D239/42 ,  C07D403/14 ,  C07D409/12 ,  C07D239/48 ,  C07D409/14 ,  C07D487/04 ,  C07D471/04 ,  C07D471/10 ,  C07D491/107 ,  C07D401/12 ,  C07D473/34 ,  C07D417/12

CPC classification number: C07D498/04 ,  C07D239/42 ,  C07D239/48 ,  C07D239/49 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D487/04 ,  C07D491/107

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11878015B2

公开(公告)日：2024-01-23

申请号：US17396187

申请日：2021-08-06

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: A61K31/506 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I):




or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US11440917B2

公开(公告)日：2022-09-13

申请号：US16804937

申请日：2020-02-28

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan X. Xiang ,  Christian Nilewski ,  Theo Michels

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20190275039A1

公开(公告)日：2019-09-12

申请号：US16233507

申请日：2018-12-27

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.